RegulatoryCompany release

Rafael Holdings files FDA application for remibetadex in Niemann-Pick C despite missed Phase 3 endpoint

🇺🇸 Rafael Holdings, Inc. (RFL) · Thu 29 Oct 2026

Subsidiary Cyclo Therapeutics has submitted an NDA and requested a rare pediatric disease priority review voucher, although the TransportNPC trial did not meet its primary endpoint overall.

Rafael Holdings said its subsidiary Cyclo Therapeutics submitted a new drug application to the US Food and Drug Administration on 28 October 2026 for remibetadex (Trappsol Cyclo) in Niemann-Pick Disease Type C. The filing includes a request for a rare pediatric disease priority review voucher.

The submission rests on the Phase 3 TransportNPC study, which missed its primary endpoint in the overall population (p=0.19). The company points to a prespecified subgroup of patients on background miglustat and/or leucine, in which it reports a 71% slowing of disease progression.

Rafael also reported results for the fiscal year ended 31 July 2026. It recorded a net loss of $29.6 million and held cash of $22.1 million, and the company disclosed substantial doubt about its ability to continue as a going concern.

For context, an NDA is the route by which a sponsor seeks FDA approval of a new medicine in the US. The agency decides whether to accept the filing for review and, if it does, assesses whether the data support approval. The source material gives no information on acceptance, review timelines or the agency's view of the subgroup analysis.

What it means for your team

  • Regulatory teams should note that the filing relies on a prespecified subgroup analysis after the overall primary endpoint was missed, so FDA's handling of the evidence will be closely watched.
  • The priority review voucher request is a pending element; no decision on the filing or the voucher has been reported.
  • Market-access and competitive-intelligence teams tracking Niemann-Pick C should factor in the sponsor's disclosed going-concern doubt when assessing development and launch continuity.

Company's press release (SEC filing): Rafael Holdings, Inc. ↗

Article written by VigiEye from the official source (Rafael Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →